Business
GCANRx Announces Relisting To OTCQB Market Tier
GCANRx Announces Relisting To OTCQB Market Tier.
About this update from Greater Cannabis Co Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n GCANRx Announces Relisting To OTCQB Market Tier\r\n \r\n \r\n\r\n\r\nGCANRx Announces Relisting To OTCQB Market Tier\r\n\r\n\r\n\r\n\r\n\r\nBaltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics, today announced that shares of its common stock were approved for quotation on the OTCQB® Venture Market. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosure. The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the Securities and Exchange Commission (SEC) as an “established public market” for the purpose of determining the public market price when registering securities for resale with the SEC. The OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements. The majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier. To learn more, visit OTCQB. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com. ENDS For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact [email protected]. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter. About Greater Cannabis Company: The Greater Cannabis Company (OTC: GCAN), (“GCANRx” or the “Company”) is a publicly traded clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. GCANRx’s mission is to bring its products ...